Log in

NASDAQ:CORVCorrevio Pharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 05/27/2020)
Today's Range
Now: $0.42
50-Day Range
MA: $0.41
52-Week Range
Now: $0.42
Average Volume5.35 million shs
Market Capitalization$27.80 million
P/E RatioN/A
Dividend YieldN/A
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CORV



Sales & Book Value

Annual Sales$32.63 million
Book Value($0.02) per share


Net Income$-35,180,000.00
Net Margins-107.81%


Market Cap$27.80 million
Next Earnings DateN/A

Receive CORV News and Ratings via Email

Sign-up to receive the latest news and ratings for CORV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Correvio Pharma (NASDAQ:CORV) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Correvio Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Correvio Pharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Correvio Pharma

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) released its quarterly earnings results on Monday, March, 30th. The company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.06. The company earned $11.33 million during the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative net margin of 107.81% and a negative return on equity of 2,128.82%.
View Correvio Pharma's earnings history

What price target have analysts set for CORV?

5 analysts have issued 12-month price objectives for Correvio Pharma's shares. Their forecasts range from $1.60 to $7.00. On average, they expect Correvio Pharma's share price to reach $4.87 in the next twelve months. This suggests a possible upside of 1,058.7% from the stock's current price.
View analysts' price targets for Correvio Pharma

Has Correvio Pharma been receiving favorable news coverage?

News articles about CORV stock have been trending very positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Correvio Pharma earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Correvio Pharma

Who are some of Correvio Pharma's key competitors?

What other stocks do shareholders of Correvio Pharma own?

Who are Correvio Pharma's key executives?

Correvio Pharma's management team includes the following people:
  • Dr. Mark H. N. Corrigan, CEO & Director (Age 62)
  • Mr. Justin A. Renz CPA, MST, M.S.T., MBA, CFO & Pres (Age 48)
  • Ms. Sheila M. Grant, Chief Operating Officer
  • Mr. David D. McMasters, Chief Compliance Officer & Gen. Counsel (Age 61)
  • Mr. Hugues Sachot, Chief Commercial Officer

What is Correvio Pharma's stock symbol?

Correvio Pharma trades on the NASDAQ under the ticker symbol "CORV."

What is Correvio Pharma's stock price today?

One share of CORV stock can currently be purchased for approximately $0.42.

How big of a company is Correvio Pharma?

Correvio Pharma has a market capitalization of $27.80 million and generates $32.63 million in revenue each year. The company earns $-35,180,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Correvio Pharma employs 133 workers across the globe.

What is Correvio Pharma's official website?

The official website for Correvio Pharma is www.correvio.com.

How can I contact Correvio Pharma?

Correvio Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The company can be reached via phone at 604-677-6905 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.